The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Towards the clinical validity of tumor organoid drug screens: Establishing a framework for organoid disease models.
 
Jessica Slostad
No Relationships to Disclose
 
Ashiq Masood
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - Astellas Pharma (Inst); Boston Biomedical (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Exelixis (Inst); Genentech/Roche (Inst); Ipsen (Inst); Macrogenics (Inst); Merck (Inst); Novocure (Inst); PRA Health (Inst); Proteus Digital Health (Inst); Seagen (Inst); Signatera (Inst); Tempus
 
April T. Swoboda
No Relationships to Disclose
 
Mia Alyce Levy
Employment - SeqTech Diagnostics (I)
Leadership - Personalis
Stock and Other Ownership Interests - GenomOncology; Personalis
Honoraria - Roche
Consulting or Advisory Role - GenomOncology, Inc; Personalis; Roche
Research Funding - GenomOncology
Patents, Royalties, Other Intellectual Property - Royalties from GenomOncology for licensing of MyCancerGenome content
Travel, Accommodations, Expenses - Roche